Table 1.

Characteristics of patients with NSCLC in the discovery cohorta

CharacteristicsDiscovery cohort (N = 35)
Median age, year (range)62 (35–83)
Male sex, n (%)20 (57.1)
Histology, n (%)
 Adenocarcinoma26 (74.3)
 Squamous cell carcinoma5 (14.3)
 Large cell carcinoma1 (2.9)
 NOS3 (8.5)
Smoking history, n (%)
 Never7 (20)
 Former14 (40)
 Current14 (40)
Molecular markers, n (%)
 No markers detected22 (62.8)
KRAS mutation9 (25.6)
EGFR mutation1 (2.9)
ALK translocation1 (2.9)
MET exon 14 deletion1 (2.9)
HER2 mutation1 (2.9)
Previous therapy lines, n (%)
 133 (84.6)
 23 (7.7)
 >23 (7.7)
ECOG PS, n (%)
 09 (25.7)
 118 (51.4)
 27 (20)
 31 (3)
  • Abbreviations: ALK, anaplastic lymphoma kinase; NOS, not otherwise specified.

  • aPatients all received nivolumab monotherapy for at least 3 cycles.